
Sign up to save your podcasts
Or


In this episode, Greg and Rob share some initial reactions around the recent judicial activity affecting HRSA's 340B rebate model. They'll discuss thoughts on the federal court ruling that halted the rebate model from going into effect, and also debate what the fallout could be for manufacturers and covered entities given the lack of a regulated deduplication process for MFP and 340B prices. They'll also discuss some of the preliminary steps hospitals might need to take in response to the CMS OPPS Drug Acquisition Cost Survey.
Email us at [email protected] if you have questions or topics for us to cover!
By SpendMend Pharmacy5
3232 ratings
In this episode, Greg and Rob share some initial reactions around the recent judicial activity affecting HRSA's 340B rebate model. They'll discuss thoughts on the federal court ruling that halted the rebate model from going into effect, and also debate what the fallout could be for manufacturers and covered entities given the lack of a regulated deduplication process for MFP and 340B prices. They'll also discuss some of the preliminary steps hospitals might need to take in response to the CMS OPPS Drug Acquisition Cost Survey.
Email us at [email protected] if you have questions or topics for us to cover!

43,735 Listeners

25,896 Listeners

3,691 Listeners

112,882 Listeners

56,980 Listeners

495 Listeners

14,303 Listeners

6,460 Listeners

23 Listeners

15,253 Listeners

3,448 Listeners

8 Listeners

4 Listeners

7 Listeners

0 Listeners